FBI Asset Ordered Terror Attack by Group Allegedly Conspiring to Storm Virginia Capitol

One of the things focused on excessively by the fake news media during the build up to today’s peaceful gun rally in Virginia has been the supposed plotting of neo-Nazis and armed militia groups to storm the Capitol.

Although none of those hysterical fears came to fruition, there were three men accused of being involved with the neo-nazi group The Base that were arrested last week. They were arrested on weapons’ charges as well as the bizarre charge of harboring an illegal immigrant from Canada. It was claimed by authorities without any evidence being provided to the public that they were planning a violent display at the Capitol rally.

While this news has been used to demonize all gun owners, startling details have emerged showing that The Base may in fact be a group run by the feds. Another Base member Yousef O. Barasneh, 22, was arrested and charged on Friday with vandalizing a Racine, WI synagogue last year. Court records show that a federal informant had been giving orders to members of the hate group to commit acts of anti-Semitic terror.

The Milwaukee Journal Sentinel reported last week that a key leader within “The Base” was a federal informant responsible ordering anti-Semitic terror attacks:

One of the group’s ringleaders became an informant and gave investigators details over the past several months. The documents in Barasneh’s case do not name the person but note he has been federally charged in another state for his role.

The man admitted he directed the group to vandalize minority-owned properties, calling it “Operation Kristallnacht,” a reference to Nazi Germany and the night Jewish homes, hospitals and other properties were ransacked and destroyed.

The man told investigators he said: “If there’s a window that wants to be broken, don’t be shy.”

This would not be the first time that the federal government has infiltrated extremist right-wing groups and made domestic terrorists into intelligence assets. The FBI infamously paid off Ku Klux Klan leader George Dorsett of Greensboro, NC for years while he was still burning crosses and fomenting the hatred of minorities.

“So sure, he’d made some fiery speeches, there’s no question about it. But if he hadn’t, he would have been worthless,” said FBI agent Dargan Frierson, who served as Dorsett’s handler, essentially laughing off Dorsett’s role in the terror group while working for the FBI.

Notorious hate monger Hal Turner was on the federal payroll as well while he issued terrorist threats on his radio show and blog page for many years:

A notorious New Jersey hate blogger charged in June with threatening to kill judges and lawmakers was secretly an FBI “agent provocateur” paid to disseminate right-wing rhetoric, his attorney said Wednesday…

“Almost everything was at the behest of the Federal Bureau of Investigation,” Orozco said in a 45-minute telephone interview from New Jersey. “Their job was to pick up information on the responses of what he was saying and see where that led them. It was an interesting dynamic on what he was being asked to do.”

“He’s a devoted American,” added the lawyer, who claims Turner was paid “tens of thousands of dollars” for his service…

https://bigleaguepolitics.com/report-federal-asset-ordered-terror-attack-by-group-allegedly-conspiring-to-storm-virginia-capitol/

African Americans are Disproportionately Affected by Vaccines

Check out this thought provoking discussion on how African Americans are disproportionately affected by vaccines leading to autoimmune conditions such as lupus and asthma. Panelists Curtis Cost, Sunayya Simon, Sister Battle and Frank Garry provide enlightening information on a little-investigated topic.

https://childrenshealthdefense.org/video/discussion-african-americans-are-disproportionately-affected-by-vaccines/

Researchers at National Jewish Health have discovered specific molecular and signaling events by which vitamin D inhibits inflammation. In their experiments, they showed that low levels of Vitamin D, comparable to levels found in millions of people, failed to inhibit the inflammatory cascade, while levels considered adequate did inhibit inflammatory signaling. They reported their results in the March 1, 2012, issue of The Journal of Immunology.

“This study goes beyond previous associations of vitamin D with various health outcomes. It outlines a clear chain of cellular events, from the binding of DNA, through a specific signaling pathway, to the reduction of proteins known to trigger inflammation,” said lead author Elena Goleva, assistant professor of pediatrics at National Jewish Health. “Patients with chronic inflammatory diseases, such as asthma, arthritis and prostate cancer, who are vitamin D deficient, may benefit from vitamin D supplementation to get their serum vitamin D levels above 30 nanograms/milliliter.”

Current national guidelines suggest that people should maintain a minimum blood serum level of 20 ng/ml, although there is much scientific debate about optimum levels. Vitamin D has long been known to contribute to bone health by promoting the absorption of calcium. In recent years, much attention has been paid to its possible immune and inflammatory benefits. Low vitamin D levels have been associated with several diseases including asthma, cancer, diabetes, and arthritis….

https://www.sciencedaily.com/releases/2012/02/120223103920.htm

Research Coverup of Vitamin D Scandal Continues

Clearly, black people aren’t getting enough access to medical care, probably because of global warming, gun rights activists and of course, Trump.

Actually “global warming” (or rather, the real government’s pretend response to it, geoengineering) is bound to affect dark skinned people disproportionately.   But who needs sunshine anyway, when we have modern medicine?

Autism prevalence and socioeconomic status

Bombshell Study Questioning HPV Vaccine Efficacy Appears as the UK’s Cervical Cancer Rates Rise in Young

Human papillomavirus (HPV) vaccines hit the global marketplace in the mid-2000s. From the start, public health agencies enthusiastically promoted HPV vaccination as the “best way to protect [young people] against certain types of cancer later in life.” However, a blistering new study by British researchers—and new data showing that cervical cancer rates are surging in British 25- to 29-year-olds—raise numerous questions about officials’ inflated claims. The study’s results indicate, instead, that the jury is still out on whether HPV vaccination is effective.

The question is far from academic because, prior to Britain’s introduction of HPV vaccination in 2008, cervical cancer rates had been trending sharply downward. In fact, between the late 1980s and mid-2000s, cervical cancer rates halved. Now, Britain’s leading cancer research charity (Cancer Research UK) reports a steep 54% rise in cervical cancer in one of the very age groups that first received the vaccine.

“Significant uncertainties”

The 2020 study, published in the Journal of the Royal Society of Medicine, critically appraises twelve published randomized controlled trials that HPV vaccine makers GlaxoSmithKline and Merck used to buttress assertions about their vaccines’ efficacy (Cervarix and Gardasil). The British authors do not beat around the bush in presenting their conclusions, which include the following:

  • The trials’ questionable methodology generated “uncertainties” so significant that they undermine claims of efficacy.
  • The ages of the women who participated in the trials were not representative of the younger adolescents who constitute HPV vaccination’s primary target groups.
  • The studies used highly restrictive criteria to exclude many potential participants, limiting the trials’ “relevance and validity for real world settings.” (During Science Day presentations for the Jennifer Robi vs. Merck and Kaiser Permanente Gardasil lawsuit in January 2019, Robert F. Kennedy, Jr. made the same point, describing the “elite club of superheroes” who constituted the study group and noting that Merck purged anyone with the slightest vulnerabilities to the vaccine or its ingredients despite the fact that the vaccine would ultimately be marketed to girls with the very vulnerabilities excluded during the clinical trials.)
  • The trials used “composite and distant surrogate outcomes” that essentially made it “impossible to determine effects on clinically significant outcomes.” The authors explain that the surrogate outcomes used (forms of cervical dysplasia called CIN1 and CIN2) often regress on their own “and are of limited clinical concern.” They also note that different forms of cervical dysplasia each have “their own different natural histories, prevalence and incidence and strength of association with cancer.” Lumping together vastly different forms of dysplasia into the trials’ composite surrogate endpoints, therefore, was “problematic.”
  • The trial investigators’ unusually frequent cervical screening of study participants likely resulted in overdiagnosis of low-grade cervical changes while overestimating the vaccines’ efficacy in preventing them. The Royal Society of Medicine authors also note that vaccine efficacy against low-grade cervical changes is no guarantee of efficacy against the higher-grade abnormalities that may contribute, along with other risk factors, to cervical cancer.
  • Most damningly, the authors argue that no certainty about whether HPV vaccination prevents cervical cancer is possible, because the trials “were not designed to detect this outcome, which takes decades to develop.”

High vaccine uptake . . . and rising cancer rates

Now consider these uncertainties against the backdrop of the United Kingdom’s HPV vaccination program—launched with great fanfare in 2008 with the bivalent Cervarix vaccine (replaced by Gardasil in 2011). The UK’s program rapidly achieved a high national uptake—on the order of 76% to 90%—making it “one of the most successful globally.” Although the HPV vaccination program primarily targeted 12-year-olds, Britain also operated a “catch-up” program during the initial three-year period (2008-2011) that encouraged girls ages 13-18 to get vaccinated. By mid-2018, the UK government estimated that 80% of 15- to 24-year-old girls and women had received the vaccine.

Given that Britain’s HPV vaccine uptake was high from the get-go, many of the women now in their mid to late twenties who are experiencing the spiking cervical cancer rate must have been among the UK’s first HPV vaccine recipients. How does this uncomfortable fact square with Public Health England’s sunny endorsement of HPV vaccination and its confident prediction (in 2018) that it would be able to “get an accurate picture of the impact this vaccine will have on this devastating cancer” as soon as vaccinated girls reached ages 25-29?

The public health agency classifies 25- to 29-year-olds as the age group most commonly affected by cervical cancer but does not mention that a cervical cancer “peak” at ages 25-29 represents a “big change” from the pattern that prevailed in Britain in previous decades—when cervical cancer peaked in women aged 50-64. In the United States, where HPV vaccine uptake has been considerably lower, women in their mid to late twenties have the second lowest cervical cancer rate, with a peak in women ages 40-44.

There are several plausible explanations for rising cervical cancer rates in the context of high vaccine uptake. One is the phenomenon known as “type replacement”—in which an HPV vaccine that covers only four to nine of the 100-200 types of HPV “may lay bare an ecological niche for non-vaccine HPV types,” some of which may be high-risk for cervical cancer. A 2016 study that analyzed the prevalence of 32 types of HPV in women with cervical abnormalities acknowledged the potential for “a continuous shift in the prevalence of HPV types as a result of vaccination” as well as the potential for increased transmission of more virulent nonvaccine types. Another study published around the same time confirmed that vaccinated women “had a higher prevalence of high-risk nonvaccine types.”

Receiving the HPV vaccine when one already has HPV is another cause for concern. In his Robi vs. Merck Science Day presentation, Robert F. Kennedy, Jr. noted that Merck’s pre-clinical trial records for Gardasil “show that girls or women who already had HPV—had been exposed at some point in their life to it—actually had a negative efficacy of 44.6 percent. What is negative efficacy? It means those girls had a 44.6 increased risk of getting those precancerous lesions.” …

https://childrenshealthdefense.org/news/bombshell-study-questioning-hpv-vaccine-efficacy-appears-as-the-uks-cervical-cancer-rates-rise-in-young/